Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Read the highlights for the 2026 World Alzheimer's Month campaign, from ADI member activities to key events and achievements from the wider community of advocates united under the theme of ‘The Earlier You Know, The More You Can Do: A Dementia Diagnosis Matters’.
ADI announces our new CEO, joining on 1 October 2026
1 September marks the beginning of World Alzheimer’s Month. This year, we are raising awareness and encouraging our global network and beyond to ask more questions about dementia.
As part of ADI's ongoing regional commitment to dementia policy, Diego Aguilar, Regional Director for the Americas, completed a high-impact country visit to Mexico that combined academic engagement, civil society coordination, and high-level government and industry dialogue.
This month, ADI’s Regional Director for the Asia Pacific, DY Suharya, partook in a number of important meetings and events both in Lyon, France at the WHO Academy, and in Hanoi, Vietnam, alongside Vietnam International Organisation for Better Ageing (VIOBA), who are currently partaking in ADI’s Membership Development Programme.
This announcement reverses an earlier recommendation made by the EMA regarding donanemab as a treatment for the treatment of early symptomatic Alzheimer's disease in adults.
This announcement reaffirms the Scottish Medicines Consortium’s decision of 10 February 2025, meaning that no disease-modifying therapies for Alzheimer’s disease are currently approved for use in Scotland.
In June, ADI’s Regional Director for the Americas, Diego Aguilar, attended a national meeting of Alzheimer’s associations in San Juan, Argentina. The meeting sought to unite lawmakers, civil society, healthcare professionals and more from across Argentina in an effort to call for legislation surrounding Alzheimer’s under the banner of #LeyAlzheimerYa (#AlzheimersLawNow).
Perceptions of dementia are dependent on many factors, such as direct personal experience with a loved one having the condition or exposure to public information campaigns, for example. Popular culture also plays a role in shaping the public discourse around dementia in ways that can have significant consequences on the…
The National Institute for Health and Care Excellence (NICE) has concluded that the benefits from two treatments for early Alzheimer's Disease, donanemab and lecanemab, remain too small to justify the additional cost. Consequently, free access to these Alzheimer's treatments will not be provided in the UK.